Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Kates

Showing results (151-160 of 157) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 157 results.
Cancers|April 13, 2024
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter RegistrySeyedeh-Sanam Ladi-Seyedian, Alireza Ghoreifi, Badrinath Konety, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder CancerAndrew B Katims, Charlie White, Syed Muneeb Alam, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 12, 2024
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome AnalysisBurles A Johnson Iii, Benjamin A Teply, Catherine Kagemann, et al.
The Journal of Urology|August 26, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialK Kent Chevli, Neal D Shore, Andrew Trainer, et al.
European Urology Oncology|April 19, 2024
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712Zaker Rana, Sophia C Kamran, Amol C Shetty, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder CancerElaine Chang, Noah M Hahn, Seth P Lerner, et al.
Pageof 16

Showing results (151-160 of 157) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
Cancers|April 13, 2024
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter RegistrySeyedeh-Sanam Ladi-Seyedian, Alireza Ghoreifi, Badrinath Konety, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder CancerAndrew B Katims, Charlie White, Syed Muneeb Alam, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 12, 2024
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome AnalysisBurles A Johnson Iii, Benjamin A Teply, Catherine Kagemann, et al.
The Journal of Urology|August 26, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialK Kent Chevli, Neal D Shore, Andrew Trainer, et al.
European Urology Oncology|April 19, 2024
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712Zaker Rana, Sophia C Kamran, Amol C Shetty, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder CancerElaine Chang, Noah M Hahn, Seth P Lerner, et al.
Pageof 16